Clinical Trial Update: Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia [Phase 2]

View source ↗

Summary

Phase 2 study evaluating ARI-3037MO to suppress LDL cholesterol in patients with hyperlipidemia; status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidemia

Drugs mentioned

• ARI-3037MO

Snippet

Sponsor: Arisaph Pharmaceuticals Inc | Conditions: Hyperlipidemia | Phase 2 | Status: UNKNOWN